Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Beats on EPS, Stock Up 1.29%

Catalyst Pharmaceuticals reported a positive surprise in EPS, which contributed to a 1.29% increase in stock price. However, there was no revenue reported or guidance provided, leaving investors with limited insight into future performance. The strong EPS could indicate better-than-expected operational efficiency or cost management.